Singapore markets open in 8 hours 55 minutes
  • Straits Times Index

    -10.61 (-0.33%)
  • S&P 500

    -4.45 (-0.11%)
  • Dow

    -37.34 (-0.11%)
  • Nasdaq

    -64.68 (-0.47%)

    +250.76 (+0.42%)
  • CMC Crypto 200

    -16.08 (-1.24%)
  • FTSE 100

    -26.63 (-0.39%)
  • Gold

    -12.30 (-0.70%)
  • Crude Oil

    +0.41 (+0.69%)
  • 10-Yr Bond

    +0.0100 (+0.60%)
  • Nikkei

    -229.33 (-0.77%)
  • Hang Seng

    -245.52 (-0.86%)
  • FTSE Bursa Malaysia

    -3.83 (-0.24%)
  • Jakarta Composite Index

    -121.64 (-2.00%)
  • PSE Index

    -26.53 (-0.41%)

BioUtah Announces CSL Limited CEO Paul Perreault as Keynote Speaker at the 2020 Virtual Utah Life Sciences Summit

·2-min read

Other headline speakers include Dr. Jeffrey Shuren, director of the Center for Devices and Radiological Health (CDHR) at the Food and Drug Administration (FDA); Dr. Peter Marks, director of the Center for Biologics Evaluation and Research (CBER) at the FDA; and more.

BioUtah today announced Paul Perreault, CEO and managing director of CSL Limited (ASX:CSL; USOTC:CSLLY) (CSL), as the awards session keynote at the 2020 Virtual Utah Life Sciences Summit (ULSS), November 9-11. To register and learn more about Mr. Perreault's keynote and agenda visit

Since being appointed CEO and managing director of CSL in July 2013, the global biotechnology leader has grown to become the third largest biotechnology company in the world and the largest company in Australia, with more than 27,000 employees providing lifesaving medicines to 100-plus countries. Harvard Business Review named Perreault as among the world’s Top 100 performing CEOs, and he has been repeatedly recognized by several influential publications as among the leading CEOs in Australia, where CSL is headquartered.

"We’re very fortunate to have Paul Perreault join us as our keynote speaker," said Kelvyn Cullimore, president and CEO of BioUtah. "Mr. Perreault will not only offer participants a unique perspective from a global rare disease powerhouse, but he will also bring to life the critical work the company is doing to fight COVID-19."

As a global leader in monoclonal antibodies, vaccines and hyperimmunes, CSL has more than five R&D programs underway to respond to the COVID-19 global pandemic. CSL is a founder of the CoVIg-19 Plasma Alliance, an unprecedented industry partnership to develop a potential plasma-derived therapy (hyperimmune intravenous immunoglobulin) to treat COVID-19. Recently, the CoVIg-19 Plasma Alliance, along with the U.S. National Institute of Allergy and Infectious Diseases at the National Institutes of Health, announced the start of a Phase 3 clinical trial of the investigational medicine. In addition, CSL is partnering with the University of Queensland in Australia and CEPI (the Coalition for Epidemic Preparedness Innovations) to accelerate, manufacture and distribute a COVID-19 vaccine should it be approved.

In addition to Mr. Perreault, the ULSS speaker line-up includes Dr. Jeffrey Shuren and Dr. Peter Marks of the FDA, as well as other industry experts. The ULSS will feature sessions tailored to Utah’s growing life sciences ecosystem, from navigating the COVID-19 crisis and funding, to regulatory compliance and leading Utah’s innovation future.

About BioUtah

BioUtah is an independent 501(c)(6) trade association serving Utah’s life sciences industry. Its member companies reflect a broad spectrum of the industry with strengths in medical device manufacturing and services, research and testing, biotechnology, biopharmaceuticals, and advanced diagnostics, amongst others; and are a key driver of Utah’s economy.

View source version on


Denise Bell